查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953946

體學化驗服務市場－全球產業規模、佔有率、趨勢、機會和預測：按服務、服務頻率、業務、最終用途、地區和競爭格局分類，2021-2031年

Omics Lab Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service, By Frequency Of Service, By Business, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球體學化驗服務市場預計將從 2025 年的 728.8 億美元成長到 2031 年的 1,284.8 億美元，複合年成長率為 9.91%。

這些服務涵蓋基因組學、蛋白質組學和代謝體學，為藥物研發和臨床應用提供關鍵的合約研究和診斷支援。推動成長的主要因素是慢性病發病率的上升，使得個人化醫療和精準分子分析的需求日益成長。此外，生物製藥公司擴大將研究活動外包給專業的外部機構，以最佳化固定成本並獲得先進技術。正如美國癌症協會所指出的，預計到2025年，美國將新增2,041,910例癌症病例，凸顯了這些先進診斷能力的重要性。

市場概覽
預測期 2027-2031
市場規模：2025年 728.8億美元
市場規模：2031年 1284.8億美元
複合年成長率：2026-2031年 9.91%
成長最快的細分市場 重複
最大的市場 北美洲

儘管市場呈現成長態勢，但由於資料隱私和倫理合規複雜的法規環境，該市場仍面臨許多挑戰。處理包含敏感基因資訊的大型資料集需要嚴格遵守不斷發展的國際標準，這導致實驗室營運成本增加，並可能帶來法律責任風險。這些嚴格的合規義務可能會延誤計劃進度，並為新進業者設定高門檻，最終阻礙創新步伐，限制市場准入。

市場促進因素

全球體學化驗服務市場的主要驅動力是個人化和精準醫療的日益融合，醫療服務提供者正轉向分子譜分析以客製化病患治療方案。這種從通用處方到標靶治療的轉變需要廣泛的基因組學、蛋白質組學和代謝體學檢測，從而推動了專業實驗室樣本處理量的激增。製藥開發商正大力投資生物標記研究以檢驗這些標靶治療，這進一步刺激了對高複雜度外包檢測的需求，以確保獲得監管部門的核准和臨床成功。根據個人化醫療聯盟 (PMC) 2025 年 5 月發布的報告《FDA 的個人化醫療：2024 年進展的範圍和意義》，FDA 預計將在 2024 年核准18 種新型個人化藥物，約佔新核准治療性分子實體的 38%。這凸顯了該產業對先進體學數據的依賴。

同時，對液態生物檢體和非侵入性診斷工具的需求不斷成長，使得在避免組織切片檢查風險的前提下，能夠頻繁監測疾病，從而擴大了市場覆蓋範圍。這種轉變迫使服務供應商擴展其定序基礎設施和生物資訊能力，以滿足癌症監測和早期檢測所需的日益增多的複雜血液生物標記檢測需求。 Guardant Health 在 2025 年 2 月發布的「2024 年第四季及全年業績」報告中指出，該公司在 2024 年處理了約 206,700 例腫瘤臨床檢測，較去年同期成長 20%。 Exact Sciences 對 2024 年全年總收入的預測進一步印證了這一趨勢的財務規模，該公司預計 2024 年全年總收入將達到 27.6 億美元，這主要得益於對其診斷和癌症篩檢服務需求的成長。

市場挑戰

全球體學化驗服務市場的一大障礙是複雜的法規結構，涵蓋資料隱私和倫理合規。實驗室處理大量的敏感基因數據，必須實施符合嚴格國際要求的複雜資料保護系統。這項要求需要投入大量資源，增加營運成本，並擠佔研發資金，往往導致計劃延期。因此，合規的財務和技術要求提高了准入門檻，阻礙了小規模、具有創新精神的公司進入市場，並促使市場被少數大型供應商壟斷。

此外，資料外洩造成的嚴重經濟損失迫使實驗室將風險管理置於服務擴張之上。安全漏洞帶來的成本高昂，並引發重大的責任問題。根據美國醫院協會發布的《2025年環境掃描報告》，2024年醫療保健資料外洩的平均成本為977萬美元。如此高的風險可能迫使各機構採用嚴格的數據處理通訊協定，從而阻礙合作研究，並降低市場提供及時便捷的診斷解決方案的能力。

市場趨勢

人工智慧 (AI) 整合在高階資料解讀領域正成為體學領域的基礎性趨勢，其關注點從提供原始資料轉向提供可操作的洞見。服務供應商正擴大將機器學習演算法融入其生物資訊學工作流程，以解讀複雜的多組體學資料集，從而幫助製藥客戶更快、更準確地發現新的治療標靶。這種向 AI 驅動的洞見生成的演進為技術先進的研究機構帶來了巨大的商機。例如，Tempus AI 在 2025 年 2 月發布的「2024 會計年度第四季及全年財務業績」中報告稱，其 2024 會計年度總收入為 6.934 億美元，同比成長 30.4%，這主要得益於其人工智慧能力的提升。

同時，空間體學和組織分析技術的興起正在變革生物分析，使基因表現能夠在組織結構背景下進行繪製。與分離細胞的傳統定序方法不同，空間分析能夠保留樣本位置資訊，從而為腫瘤微環境和細胞間相互作用提供關鍵見解，這對於腫瘤免疫學至關重要。這項進步正推動研究實驗室大力投資高通量成像和空間分辨轉錄組學，以滿足日益成長的生物製藥需求。為了佐證這一趨勢，10x Genomics 在其於 2025 年 1 月發布的「2024 年第四季及全年初步業績報告」中指出，2024 年全年空間分析耗材銷售額達到約 1.211 億美元，表明這些具有上下文感知能力的解決方案正在被業界迅速採用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球體學化驗服務市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依服務領域（基因體學、蛋白質體學、轉錄體學、代謝體學、表觀遺傳學）
    • 按服務頻率（一次性、定期、持續性）
    • 依業務類型（醫院、研究機構、診斷檢查室）
    • 依最終用途（癌症、藥物、生殖、其他遺傳疾病）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美體學化驗服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲體學化驗服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區體學化驗服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲體學化驗服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲體學化驗服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球體學化驗服務市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • Q2 Solutions LLC
  • Flomics Biotech
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc
  • Quest Diagnostics Incorporated
  • Phenoswitch Bioscience Inc.
  • Spectrus Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16260

The Global Omics Lab Services Market is projected to expand from USD 72.88 Billion in 2025 to USD 128.48 Billion by 2031, registering a CAGR of 9.91%. These services, which include genomics, proteomics, and metabolomics, provide essential contract research and diagnostic support for pharmaceutical development and clinical applications. Growth is largely driven by the rising incidence of chronic diseases, which accelerates the need for personalized medicine and accurate molecular profiling. Additionally, biopharmaceutical firms are increasingly outsourcing research activities to external specialists to optimize fixed costs and access advanced expertise. As highlighted by the American Cancer Society, an estimated 2,041,910 new cancer cases are expected in the United States in 2025, underscoring the critical need for these sophisticated diagnostic capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 72.88 Billion
Market Size 2031USD 128.48 Billion
CAGR 2026-20319.91%
Fastest Growing SegmentRepeat
Largest MarketNorth America

Despite this growth, the market faces significant hurdles due to the intricate regulatory environment surrounding data privacy and ethical compliance. Handling vast datasets with sensitive genetic details demands rigorous adherence to shifting international standards, resulting in elevated operational expenses and potential liability risks for laboratories. These strict compliance obligations can prolong project timelines and establish high barriers for new entrants, ultimately impeding the rate of innovation and limiting market accessibility.

Market Driver

The Global Omics Lab Services Market is significantly propelled by the increasing integration of personalized and precision medicine, as healthcare providers turn to molecular profiling to customize patient treatments. This transition from generalized prescribing to targeted therapeutic approaches requires extensive genomic, proteomic, and metabolomic testing, thereby boosting the volume of samples processed by specialized labs. Pharmaceutical developers are heavily investing in biomarker research to validate these targeted therapies, fueling the demand for outsourced, high-complexity testing to ensure regulatory approval and clinical success. According to the Personalized Medicine Coalition's May 2025 report, 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024,' the FDA approved 18 new personalized medicines in 2024, representing roughly 38% of all newly approved therapeutic molecular entities, which highlights the industry's reliance on advanced omics data.

Concurrently, the rising demand for liquid biopsy and non-invasive diagnostic tools is widening the market scope by facilitating frequent disease monitoring without the risks involved in tissue biopsies. This shift compels service providers to expand their sequencing infrastructure and bioinformatic capabilities to manage the growing influx of complex blood-based biomarker tests needed for cancer surveillance and early detection. Guardant Health reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 that it processed approximately 206,700 oncology clinical tests during 2024, a 20% increase year-over-year. The financial magnitude of this trend is further demonstrated by Exact Sciences, which reported total revenue of $2.76 billion for the full year 2024 in 2025, largely attributed to the strong uptake of its diagnostic and cancer screening services.

Market Challenge

A major obstacle to the Global Omics Lab Services Market is the intricate regulatory framework governing data privacy and ethical compliance. Because laboratories handle vast amounts of sensitive genetic data, they must implement advanced data protection systems to satisfy strict international requirements. This necessity requires significant resource allocation, which increases operational costs and diverts funds away from research and development, often leading to project delays. Consequently, the financial and technical demands of compliance establish high barriers to entry, deterring smaller, innovative companies and favoring market consolidation among a few large providers.

Additionally, the severe financial implications of data breaches force laboratories to prioritize risk management over service expansion. The costs associated with security failures are prohibitive and pose significant liability concerns; the American Hospital Association's 2025 Environmental Scan report noted that the average cost of a healthcare data breach in 2024 was $9.77 million. Such high risks drive organizations to adopt restrictive data handling protocols, which can impede collaborative research efforts and slow the market's capacity to provide timely and accessible diagnostic solutions.

Market Trends

The integration of Artificial Intelligence for advanced data interpretation is emerging as a cornerstone trend in the omics sector, shifting the focus from delivering raw sequencing data to providing actionable insights. Service providers are increasingly incorporating machine learning algorithms into their bioinformatics workflows to decode complex multi-omics datasets, enabling pharmaceutical clients to discover new therapeutic targets more rapidly and accurately. This evolution toward AI-driven insight generation offers significant revenue potential for technologically advanced labs. For instance, Tempus AI reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 that it achieved a total revenue of $693.4 million for the fiscal year 2024, marking a 30.4% year-over-year increase driven largely by its enhanced AI-enabled capabilities.

In parallel, the rise of Spatial Omics and tissue profiling technologies is transforming biological analysis by allowing researchers to map gene expression within the architectural context of tissue. Unlike traditional sequencing methods that dissociate cells, spatial profiling maintains the sample's positional integrity, offering vital insights into tumor microenvironments and cellular interactions crucial for immuno-oncology. This advancement has prompted laboratories to invest significantly in high-plex imaging and spatially resolved transcriptomics to satisfy growing biopharma demand. Highlighting this trend, 10x Genomics reported in its 'Preliminary Select Fourth Quarter and Full Year 2024 Results' in January 2025 that it generated approximately $121.1 million in spatial consumables revenue for the full year 2024, demonstrating the rapid industry adoption of these context-aware solutions.

Key Market Players

  • Agilent Technologies, Inc.
  • Q2 Solutions LLC
  • Flomics Biotech
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc
  • Quest Diagnostics Incorporated
  • Phenoswitch Bioscience Inc.
  • Spectrus Corporation

Report Scope

In this report, the Global Omics Lab Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omics Lab Services Market, By Service

  • Genomics
  • Proteomics
  • Transcriptomics
  • Metabolomics
  • Epigenetics

Omics Lab Services Market, By Frequency Of Service

  • One-Off
  • Repeat
  • Continuous

Omics Lab Services Market, By Business

  • Hospitals
  • Research Institutes
  • Diagnostic Labs

Omics Lab Services Market, By End Use

  • Cancer
  • Pharmaco
  • Reproductive
  • Other Genetic Disease

Omics Lab Services Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omics Lab Services Market.

Available Customizations:

Global Omics Lab Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics Lab Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Genomics, Proteomics, Transcriptomics, Metabolomics, Epigenetics)
    • 5.2.2. By Frequency Of Service (One-Off, Repeat, Continuous)
    • 5.2.3. By Business (Hospitals, Research Institutes, Diagnostic Labs)
    • 5.2.4. By End Use (Cancer, Pharmaco, Reproductive, Other Genetic Disease)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Omics Lab Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service
    • 6.2.2. By Frequency Of Service
    • 6.2.3. By Business
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Omics Lab Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Frequency Of Service
        • 6.3.1.2.3. By Business
        • 6.3.1.2.4. By End Use
    • 6.3.2. Canada Omics Lab Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Frequency Of Service
        • 6.3.2.2.3. By Business
        • 6.3.2.2.4. By End Use
    • 6.3.3. Mexico Omics Lab Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Frequency Of Service
        • 6.3.3.2.3. By Business
        • 6.3.3.2.4. By End Use

7. Europe Omics Lab Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service
    • 7.2.2. By Frequency Of Service
    • 7.2.3. By Business
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Omics Lab Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Frequency Of Service
        • 7.3.1.2.3. By Business
        • 7.3.1.2.4. By End Use
    • 7.3.2. France Omics Lab Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Frequency Of Service
        • 7.3.2.2.3. By Business
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Omics Lab Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Frequency Of Service
        • 7.3.3.2.3. By Business
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Omics Lab Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Frequency Of Service
        • 7.3.4.2.3. By Business
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Omics Lab Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Frequency Of Service
        • 7.3.5.2.3. By Business
        • 7.3.5.2.4. By End Use

8. Asia Pacific Omics Lab Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service
    • 8.2.2. By Frequency Of Service
    • 8.2.3. By Business
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Omics Lab Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Frequency Of Service
        • 8.3.1.2.3. By Business
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Omics Lab Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Frequency Of Service
        • 8.3.2.2.3. By Business
        • 8.3.2.2.4. By End Use
    • 8.3.3. Japan Omics Lab Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Frequency Of Service
        • 8.3.3.2.3. By Business
        • 8.3.3.2.4. By End Use
    • 8.3.4. South Korea Omics Lab Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Frequency Of Service
        • 8.3.4.2.3. By Business
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Omics Lab Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Frequency Of Service
        • 8.3.5.2.3. By Business
        • 8.3.5.2.4. By End Use

9. Middle East & Africa Omics Lab Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service
    • 9.2.2. By Frequency Of Service
    • 9.2.3. By Business
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Omics Lab Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Frequency Of Service
        • 9.3.1.2.3. By Business
        • 9.3.1.2.4. By End Use
    • 9.3.2. UAE Omics Lab Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Frequency Of Service
        • 9.3.2.2.3. By Business
        • 9.3.2.2.4. By End Use
    • 9.3.3. South Africa Omics Lab Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Frequency Of Service
        • 9.3.3.2.3. By Business
        • 9.3.3.2.4. By End Use

10. South America Omics Lab Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service
    • 10.2.2. By Frequency Of Service
    • 10.2.3. By Business
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Omics Lab Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Frequency Of Service
        • 10.3.1.2.3. By Business
        • 10.3.1.2.4. By End Use
    • 10.3.2. Colombia Omics Lab Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Frequency Of Service
        • 10.3.2.2.3. By Business
        • 10.3.2.2.4. By End Use
    • 10.3.3. Argentina Omics Lab Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Frequency Of Service
        • 10.3.3.2.3. By Business
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Omics Lab Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Q2 Solutions LLC
  • 15.3. Flomics Biotech
  • 15.4. QIAGEN N.V.
  • 15.5. Thermo Fisher Scientific Inc.
  • 15.6. Illumina, Inc
  • 15.7. Quest Diagnostics Incorporated
  • 15.8. Phenoswitch Bioscience Inc.
  • 15.9. Spectrus Corporation

16. Strategic Recommendations

17. About Us & Disclaimer